Rocket Pharmaceuticals
New York, New York, United States · Biotechnology, Genetics, Health Care
Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company seeking gene therapy cures. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for our mission and making a difference for
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 262
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (RCKT)
- Website
- rocketpharma.com
- Company page
Recent activity at Rocket Pharmaceuticals
- : SEC 8-K (1.01): On September 30, 2026, Rocket Pharmaceuticals, Inc. entered into a Loan and Security Agreement providing for up to five tranches of senior secured term loans totaling $150 million. The agreement includes a fully funded Tranche 1-A of $35 million as of the closing date, with subsequent tranches available based on specified milestones and borrower options. Key components include an interest rate set at the greater of the prime rate or 6.75%, plus 2.40%, and a maturity date of October 1, 2030, extendable under certain conditions. This agreement is crucial for the Company's funding strategy and potential FDA approval of a new treatment for Danon Disease.
- : SEC 8-K (7.01): On September 15, 2026, Rocket Pharmaceuticals, Inc. announced a significant alignment with the U.S. FDA concerning the global pivotal Phase 2 trial of its product RP-A501 for treating Danon disease. The announcement included details about the recalibrated dosing strategy, a pivotal population of 12 patients, and established 12-month co-primary endpoints. This development signifies progress in the clinical trial process, which is crucial for the company's ongoing efforts to bring this treatment to market. The press release serves as a key communication to stakeholders about the trial advancements and regulatory compliance.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On August 3, 2026, Rocket Pharmaceuticals, Inc. announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. This update was disseminated through a press release, which is included as Exhibit 99.1. The announcement is significant for stakeholders as it provides critical information on the progress of a key clinical trial that could impact future developments and strategic directions for the company. The trial's success is essential for Rocket's efforts in developing treatments for Danon disease, a rare but serious condition.
- : SEC 8-K (5.02):
- : SEC 8-K (2.01): On June 10, 2026, Rocket Pharmaceuticals, Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company, following the terms set in an asset purchase agreement dated April 26, 2026. The company received gross proceeds of $180 million upon closing the asset sale, which is significant in relation to the company’s ongoing development of its gene therapy KRESLADI™. The transaction is expected to enhance the company’s financial position and enable further investments in research and development. Details regarding the asset purchase agreement will be included in the Company’s upcoming Quarterly Report on Form 10-Q for the period ending June 30, 2026.
- : SEC 8-K (1.01): On April 26, 2026, Rocket Pharmaceuticals, Inc. entered into a definitive asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million cash. This PRV was linked to the FDA approval of KRESLADI™, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I. The transaction is subject to customary closing conditions, including antitrust reviews. This agreement significantly impacts Rocket's financial position and strategic focus in pediatric therapies.
- : SEC 8-K (7.01): On March 27, 2026, Rocket Pharmaceuticals, Inc. announced through a press release that the FDA approved their gene therapy, KRESLADI™ (marnetegragene autotemcel), for treating severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients. The approval also granted the Company a Rare Pediatric Disease Priority Review Voucher (PRV), aiming to encourage the development of therapies for rare pediatric diseases. Rocket Pharmaceuticals plans to evaluate strategic options for monetizing the PRV to enhance financial flexibility and maximize shareholder value. This significant regulatory approval marks an important milestone for the Company's product pipeline and potential market strategy.
- : SEC 8-K (1.01): On March 10, 2026, Rocket Pharmaceuticals, Inc. entered into a Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market offering program. Under this agreement, the Company intends to offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000. The shares will be offered under a shelf registration statement on Form S-3 that was filed with the SEC on March 2, 2026. This arrangement allows Rocket Pharmaceuticals flexibility to raise capital as needed, which could be pivotal for their ongoing operations and future developments.
- : SEC 8-K (1.01): On March 10, 2026, Rocket Pharmaceuticals, Inc. entered into a Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market offering program allowing the Company to sell up to $100,000,000 of its common stock at its discretion. The Sales Agreement will utilize the Company's recently filed shelf registration statement on Form S-3. The Sales Agent will receive up to a 3.0% commission on gross proceeds. The offering can be suspended or terminated per the terms set forth in the agreement, with the sale of Shares terminating upon completion of the offering or following termination of the Sales Agreement.
Leadership
- Thomas Faria, Vice President, Head of Global Medical Affairs
- Chris Stevens, Chief Operating Officer
- Sarbani Chaudhuri, Chief Commercial Officer
- Aaron Ondrey, Chief Financial Officer
Verified email and direct lines for Rocket Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Rocket Pharmaceuticals in the news
- Rocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Under Modified Phase 2 Protocol in Danon Disease - BioPharm International (Aug 03, 2026)
- Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire (Mar 27, 2026)
- FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder - MedCity News (Mar 29, 2026)
- Rocket Pharma's shares soar after US FDA lets gene therapy trial resume - Reuters (Aug 20, 2025)
- Patient dies in Rocket’s Phase II Danon disease gene therapy trial - Clinical Trials Arena (May 27, 2025)
- Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference - Business Wire (Oct 15, 2026)
- Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress - Business Wire (May 07, 2026)
- Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million - Business Wire (Jun 12, 2026)
Companies similar to Rocket Pharmaceuticals
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Genethon · Biotechnology, Genetics, Health Care, Therapeutics
- Prime Medicine · Biotechnology, Genetics, Health Care, Therapeutics
- Sangamo Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
About Rocket Pharmaceuticals: questions and answers
What does Rocket Pharmaceuticals do?
Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company seeking gene therapy cures. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for our mission and making a difference for
Where is Rocket Pharmaceuticals headquartered?
Rocket Pharmaceuticals is headquartered in New York, New York, United States.
How many employees does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has about 262 employees.
Who leads Rocket Pharmaceuticals?
Thomas Faria is a Vice President, Head of Global Medical Affairs at Rocket Pharmaceuticals.
What is the latest news on Rocket Pharmaceuticals?
On Oct 06, 2026, SEC 8-K (1.01): On September 30, 2026, Rocket Pharmaceuticals, Inc. entered into a Loan and Security Agreement providing for up to five tranches of senior secured term loans totaling $150 million. The agreement includes a fully funded Tranche 1-A of $35 million as of the closing date, with subsequen
Is Rocket Pharmaceuticals a public company?
Yes. Rocket Pharmaceuticals is publicly traded under the ticker RCKT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy